High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer
نویسندگان
چکیده
منابع مشابه
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
PURPOSE The aims of this study were to compare in a randomized trial the results of high-dose versus conventional-dose chemotherapy as first-line treatment for metastatic breast cancer. The comparison included complete response (CR) rate, duration of response, and duration of survival. PATIENTS AND METHODS Ninety patients were entered onto a study to compare two cycles of high-dose cyclophosp...
متن کاملHigh-dose chemotherapy for breast cancer: the French PEGASE experience.
BACKGROUND Early studies of high-dose chemotherapy (HDC) for breast cancer were limited by small numbers and the lack of adequate control groups. The French PEGASE Group was founded to perform larger and properly randomized comparative studies of this approach. METHODS The program was created to determine the effects of intensive chemotherapy for breast cancer. The seven PEGASE protocols addr...
متن کاملHigh-dose chemotherapy for breast cancer: evolving data.
Despite a recent decline in incidence and mortality, breast cancer currently develops in one of eight North American women who live to 85 years of age, and remains the major cause of death in American women between the ages of 15 and 54.[1,2] Data from historical series and the results of cooperative group adjuvant trials from the 1970s and 80s indicate that mortality at 10 years in women who ...
متن کاملMetronomic Chemotherapy for Metastatic Breast Cancer
The present study demonstrates that metronomic docetaxel–capecitabine chemotherapy with daily celecoxib can produce significant anticancer activity, with predictable toxicity. Efficacy fell short of expectations, with outcome measures being similar to those obtained when the study agents are given in conventional dosing. Furthermore, there is mounting evidence to indicate that a low dose of tax...
متن کاملAdvances in Chemotherapy for Metastatic Breast Cancer
Despite many advances over the past few years in the adjuvant treatment of breast cancer, a significant number of patients develop metastatic disease. Furthermore, a small yet consistent percentage of women are diagnosed with de novo metastatic disease. Once the disease has spread outside the locoregional area of the breast and draining lymph nodes, it is considered incurable, historically with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1994
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19940401)73:7<1842::aid-cncr2820730711>3.0.co;2-f